Search company, investor...

Profectus BioSciences

profectusbiosciences.net

Founded Year

2003

Stage

Grant - III | Alive

Total Raised

$29.04M

About Profectus BioSciences

Profectus Biosciences is a technology based vaccine company devoted to the treatment and prevention of chronic viral diseases. The Company's name, Profectus, when translated from its Latin roots, means"to advance or improve". The Company's proof of concept target is human immunodeficiency virus (HIV) with an intermediate term focus on hepatitis C virus (HCV).

Headquarters Location

6411 Beckley Street Suite N201

Baltimore, Maryland, 21224,

United States

443-743-1100

Missing: Profectus BioSciences's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Profectus BioSciences's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Profectus BioSciences

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Profectus BioSciences is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Profectus BioSciences Patents

Profectus BioSciences has filed 1 patent.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

2/27/2015

4/3/2018

Molecular biology, RNA, Gene expression, Transcription factors, DNA

Grant

Application Date

2/27/2015

Grant Date

4/3/2018

Title

Related Topics

Molecular biology, RNA, Gene expression, Transcription factors, DNA

Status

Grant

Latest Profectus BioSciences News

Aurobindo Pharma working on COVID-19 vaccine; shortlisted for BIRAC funding

Aug 7, 2020

"During the year (FY20), we have further strengthened our presence in the vaccines segment through the acquisition of R&D assets from Profectus Biosciences through Auro Vaccines. Using those R&D assets, the team is working on developing several viral vaccines, including a vaccine for COVID-19," it said. PTI × Aurobindo Pharma Limited is working on developing several viral vaccines including one for COVID-19 even as the candidate was approved for funding by the Department of BioTechnology, the company said in its latest annual report. "During the year (FY20), we have further strengthened our presence in the vaccines segment through the acquisition of R&D assets from Profectus Biosciences through Auro Vaccines. Using those R&D assets, the team is working on developing several viral vaccines, including a vaccine for COVID-19," it said. In November 2019, Aurobindo Pharma said its subsidiary Auro Vaccines LLC entered into a pact to acquire certain business assets from Profectus BioSciences Inc USA for an upfront cash consideration of USD 11.29 million (around Rs 80 crore) with potential earn-outs on achieving certain milestones. "Our vaccine candidate underwent an evaluation by BIRAC (Biotechnology Industry Research Assistance Council, Department of BioTechnology). BIRAC has evaluated our platform extensively and we have been informed that our vaccine has been shortlisted by BIRAC for funding initial development up," the city-based drug maker said in the annual report. related news The global market size of the product is USD 6.2 billion. The company has successfully completed the Phase-I and Phase II studies. Phase-III clinical study is expected to be initiated by December 2020. The final product would be launched by the end of FY22, Aurobindo said. "The acquisition (of Profectus BioSciences) will also lead to the enhancement of our R&D capabilities and expertise in developing new vaccines from basic discovery to FDA approved products. As part of our commitment to patient needs, we have started working on developing a vaccine for COVID- 19," the report said. Aurobindo is setting up manufacturing facilities for orals in China, injectables and other routes of administration like patches, topicals, inhalers, among others in India and in the USA. Also, its biosimilars (Unit XVII) and vaccines facilities (Unit XVIII) are ready for commercialisation. The COVID-19 pandemic impacted select business segments like generic injectables due to a decline in in- patient volumes and out-patient footfalls in the hospitals during the last fiscal. However, the muted growth was offset by volume improvement in other businesses. First Published on Aug 7, 2020 11:42 am

Profectus BioSciences Frequently Asked Questions (FAQ)

  • When was Profectus BioSciences founded?

    Profectus BioSciences was founded in 2003.

  • Where is Profectus BioSciences's headquarters?

    Profectus BioSciences's headquarters is located at 6411 Beckley Street, Baltimore.

  • What is Profectus BioSciences's latest funding round?

    Profectus BioSciences's latest funding round is Grant - III.

  • How much did Profectus BioSciences raise?

    Profectus BioSciences raised a total of $29.04M.

  • Who are the investors of Profectus BioSciences?

    Investors of Profectus BioSciences include Coalition for Epidemic Preparedness Innovations, U.S. Department of Health and Human Services, Cross Atlantic Capital Partners, PATH Malaria Vaccine Initiative and National Institutes of Health.

  • Who are Profectus BioSciences's competitors?

    Competitors of Profectus BioSciences include Humanetics, CoImmune, Immune Targeting Systems, Okairos, Lux Biosciences and 15 more.

Compare Profectus BioSciences to Competitors

O
Opal Therapeutics

Opal Therapeutics is an immunotherapy company focused on therapies for human immunodeficiency virus (HIV) and Hepatitis C (HCV), based on technology from the University of Melbourne.

P
Panacos Pharmaceuticals

Panacos is developing anti-infective products through discovery and development of small molecule oral drugs for the treatment of HIV and other major human viral diseases. Per the company, Panacos' proprietary discovery technologies are designed to combat resistance by focusing on novel targets in the virus life cycle, including virus maturation and virus fusion.

S
Savine Therapeutics

The focus of Savine Therapeutics is to develop and commercialise vaccines for prevention and treatment of diseases using it's Scrambled Antigen Vaccine (SAVINE) technology. The technology was invented by researchers in the John Curtin School of Medical Research at the Australian National University. Per the company, it enables production of vaccines suitable for a broad range of serious worldwide infectious diseases and cancers. See www.savine.com

H
Humanetics

Humanetics is a clinical-stage pharmaceutical company engaged in developing and commercializing products to enhance human health and wellbeing in markets with urgent and unmet needs. It has a focus on radiation modulators for oncology, medical imaging, and medical countermeasure uses. The company develops BIO 300, a highly selective modulator of inflammation, cell cycle arrest, and DNA damage repair. Humanetics was founded in 1988 and is based in Minneapolis, Minnesota.

I
Intarcia Therapeutics

Intarcia Therapeutics is a biopharmaceutical company based in Boston, Massachusetts. Intarcia is engaged in the development of a pipeline of products for the proprietary Medici Drug Delivery System comprised of three technologies: A stabilization technology that allows for proteins, peptides, antibody fragments, and other highly potent small molecules to be stabilized at or above human body temperatures, a matchstick-sized osmotic mini-pump that is placed under the dermal layer of skin to deliver a continuous and consistent flow of medication, and a placement technology including proprietary tools designed to provide an optimal user experience.

K
Koronis Pharmaceuticals

Koronis Pharma develops antiviral therapeutics based on Viral Decay Acceleration, which exploits the strength of a virus to target its collapse.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.